Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C88342
http://purl.obolibrary.org/obo/NCIT_C88342
|
|---|---|
| Preferred Name | CpG Oligodeoxynucleotide GNKG168 |
| Definitions |
A synthetic, 21-mer, unmethylated CpG motif-based oligodeoxynucleotide (ODN), with immunostimulatory activity. CpG oligodeoxynucleotide GNKG168 binds to and activates Toll-like receptor 9 (TLR9) and is taken up into cells by endocytosis; once internalized, it may activate numerous signaling transduction pathways resulting in the release of multiple cytokines, such as immunoglobulins (Igs), interferons (IFNs), interleukins (ILs) and tumor necrosis factor (TNF). Through activation of TLR9, this ODN can directly stimulate B-lymphocytes, dendritic and natural killer (NK) cells, resulting in an increase in innate immunity and antibody-dependent cellular cytotoxicity (ADCC). In addition, through the release of IL-12 and IFN, this agent may induce a preferential shift to the T-helper 1(Th1) phenotype resulting in enhanced CD8+ T cell-mediated antitumor cytotoxicity.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic, 21-mer, unmethylated CpG motif-based oligodeoxynucleotide (ODN), with immunostimulatory activity. CpG oligodeoxynucleotide GNKG168 binds to and activates Toll-like receptor 9 (TLR9) and is taken up into cells by endocytosis; once internalized, it may activate numerous signaling transduction pathways resulting in the release of multiple cytokines, such as immunoglobulins (Igs), interferons (IFNs), interleukins (ILs) and tumor necrosis factor (TNF). Through activation of TLR9, this ODN can directly stimulate B-lymphocytes, dendritic and natural killer (NK) cells, resulting in an increase in innate immunity and antibody-dependent cellular cytotoxicity (ADCC). In addition, through the release of IL-12 and IFN, this agent may induce a preferential shift to the T-helper 1(Th1) phenotype resulting in enhanced CD8+ T cell-mediated antitumor cytotoxicity. |
|---|---|
| prefLabel | CpG Oligodeoxynucleotide GNKG168
|
| label | CpG Oligodeoxynucleotide GNKG168
|
| PDQ_Closed_Trial_Search_ID | 662816
|
| code | C88342
|
| Has_Target | |
| prefixIRI | NCIT:C88342
|
| in_subset |
See more
See less
|
| Display_Name | CpG Oligodeoxynucleotide GNKG168
|
| Preferred_Name | CpG Oligodeoxynucleotide GNKG168
|
| FDA_UNII_Code | JK03C8HWHK
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | CpG Oligodeoxynucleotide GNKG168
|
| NCI_Drug_Dictionary_ID | 662816
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 662816
|
| Semantic_Type |
Pharmacologic Substance
Nucleic Acid, Nucleoside, or Nucleotide
|
| UMLS_CUI | C2981861
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |